Hiroshi Hongo, MD, PhD

I am exploring mechanisms of drug resistance in aggressive variant and neuroendocrine  prostate cancer.
​
Awards: 

• The Uehara Memorial Foundation Fellowship
• Young Investigator Award, Keio University School of Medicine Alumni Association (Sanshikai)
• The 109th Japanese Urological Association (JUA) Annual Meeting Award
• The 108th JUA Annual Meeting Award
• The 76th JUA Sakaguchi Prize
• American Urological Association (AUA) 2018 Annual Meeting Best Poster Award

Select Publications: 

1. Hongo H et al. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration resistant prostate cancer by in silico screening. Prostate Cancer Prostatic Dis. 2023
2. Hongo H et al. BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy. Asian J. Androl. 2022
3. Hongo H et al. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways. Sci Rep. 2021
4. Hongo H et al. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer. Cancer Sci. 2018